Portal de investigación
Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Watts, Justin M.
- Baer, Maria R.
- Yang, Jay
- Prebet, Thomas
- Lee, Sangmin
- Schiller, Gary J.
- Dinner, Shira
- Pigneux, Arnaud
- Wang, Eunice S.
- Seiter, Karen
- Wei, Andrew H.
- De Botton, Stephane
- Sangerman, Montserrat Arnan
- Donnellan, William B.
- Jonas, Brian A.
- Ferrell, Paul Brent, Jr.
- Dao, Kim-Hien
- Kelly, Patrick
- Sweeney, Jennifer
- Forsyth, Sanjeev
- Guichard, Sylvie
- Brevard, Julie
- Henrick, Patrick
- Mohamed, Hesham
- Cortes, Jorge E.
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 5,416 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Citas Recibidas en Web of Science: 17
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Watts,JM,Baer,MR,Yang,J,Prebet,T,Lee,S,Schiller,GJ,Dinner,S et al. Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). 2019. Orlando-FL. RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS:ELSEVIER. 2019.